Comparative Pharmacology
Head-to-head clinical analysis: CELONTIN versus LAMICTAL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CELONTIN versus LAMICTAL XR.
CELONTIN vs LAMICTAL XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases levels of gamma-aminobutyric acid (GABA) in the central nervous system, possibly by inhibiting GABA transaminase or enhancing GABA release; also reduces calcium influx into neurons, stabilizing neuronal membranes.
Lamotrigine inhibits voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting the release of excitatory neurotransmitters such as glutamate and aspartate.
300 mg orally three times daily, increased by 300 mg every 3-4 days as tolerated; usual maintenance dose 900-2400 mg/day in divided doses.
Lamotrigine extended-release tablets: Initial 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 1 week, then 200 mg once daily; maintenance 200–400 mg once daily as adjunctive therapy for epilepsy. For bipolar disorder, dose titration as per prescribing information; typical maintenance 200 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in adults, 30-45 hours in children; prolonged liver disease or renal impairment may increase half-life.
Terminal elimination half-life is approximately 25-33 hours in healthy adults, increasing to 50-60 hours in patients taking valproate, and decreasing to 15-27 hours in patients taking enzyme-inducing drugs like carbamazepine, phenytoin, or phenobarbital.
Renal: approximately 40-60% as unchanged drug; hepatic metabolism accounts for the remainder, with metabolites excreted renally.
Primarily renal; ~70% of lamotrigine is excreted in urine as glucuronide conjugates, 10% as parent drug, and 20% via feces.
Category C
Category C
Anticonvulsant
Anticonvulsant